Seroconversion from Anti-Th/To to Anticentromere Antibodies in a Patient with Systemic Sclerosis

Koenig, Martial; Senécal, Jean‐Luc; Mähler, Michael

doi:10.3899/jrheum.170575

Cited by 5 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 3 of these patients, a modification of their clinical phenotype was identified. There has been only one case report of a patient converting from anti Th/To to ACA 27 , although neither of these autoantibodies were present in our seroconversion cohort. The seroconversion also predated any change in clinical phenotype.…”

Section: Discussionmentioning

confidence: 78%

Combinations of scleroderma hallmark autoantibodies associate with distinct clinical phenotypes

Clark

Campochiaro

Host

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Systemic sclerosis (SSc) is characterized by the presence of SSc-specific or SSc-associated antibodies (SSc-Abs): anti-topoisomerase I (ATA), anti-centromere (ACA), anti-RNA polymerase III (ARA), anti-U3RNP (U3RNP), anti-U1RNP (U1RNP), anti-PmScl (PmScl), anti-Ku (Ku) and anti-Th/To (Th/To), each being associated with specific clinical features and prognosis. The detection of more than one SSc-Abs in SSc patients is rare and only few data about these patients’ clinical phenotype is available. The aim of our study was to evaluate the frequency and the disease’s features associated with the presence of > 1 SSc-Abs positivity in a large cohort of SSc patients. The autoantibody profiles of 2799 SSc patients from February 2001 to June 2017 were retrospectively reviewed. Patients with > 1 SSc-Abs were identified. Clinical features were collected and compared to a large historical cohort of SSc patients with single SSc-Ab positivity. SSc patients were excluded if previously treated with rituximab, intravenous immunoglobulins or stem cell transplantation. Non-parametric tests were used for statistical analysis. Nearly 5% of SSc patients from our cohort had ≥ 2 autoantibody positivity, and 2.3% (n = 72) had ≥ 2 SSc-Abs positivity. Th e most common combination was U1RNP and ATA (35%). These patients were younger than patients with single autoantibody positivity and showed more commonly a diffuse cutaneous SSc form. They also had higher rates of overlap features compared to ATA patients. Other combinations included U1RNP and ACA (13%), ATA and ACA (7%) and U1RNP and PmScl (5%). In our study we observed that, while infrequently, SSc patients can present with a combination of two SSc-Abs and that the double positivity can influence their clinical phenotype compared to patients with single SSc-Ab positivity. The importance of re-testing SSc-Abs in patients with changing clinical phenotypes was also highlighted, as this may confer a differing risk stratification.

show abstract

Section: Discussionmentioning

confidence: 78%

Combinations of scleroderma hallmark autoantibodies associate with distinct clinical phenotypes

Clark

Campochiaro

Host

et al. 2022

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Historically, it is established that autoantibody specificities in SSc are rather stable. However, a recent case report on anti-Th/To antibodies has shown significant fluctuations in antibody levels and also seroconversion (switch in autoantibody profile) [ 58 ]. The stability of anti-U11/U12 antibody levels might have significant implications on the interpretation of previous data including their association with cancer.…”

Section: Other Considerationsmentioning

confidence: 99%

Anti-U11/U12 Antibodies as a Rare but Important Biomarker in Patients with Systemic Sclerosis: A Narrative Review

Fritzler

Bentow²,

Beretta

et al. 2023

Diagnostics

Self Cite

View full text Add to dashboard Cite

Anti-nuclear (ANA) are present in approximately 90% of systemic sclerosis (SSc) patients and are key biomarkers in supporting the diagnosis and determining the prognosis of this disease. In addition to the classification criteria autoantibodies for SSc [i.e., anti-centromere, anti-topoisomerase I (Scl-70), anti-RNA polymerase III], other autoantibodies have been associated with important SSc phenotypes. Among them, anti-U11/U12 ribonucleoprotein (RNP) antibodies, also known as anti-RNPC-3, were first reported in a patient with SSc, but very little is known about their association and clinical utility. The U11/U12 RNP macromolecular complex consists of several proteins involved in alternative mRNA splicing. More recent studies demonstrated associations of anti-anti-U11/U12 antibodies with SSc and severe pulmonary fibrosis as well as with moderate to severe gastrointestinal dysmotility. Lastly, anti-U11/U12 autoantibodies have been strongly associated with malignancy in SSc patients. Here, we aimed to summarize the knowledge of anti-U11/U12/RNPC-3 antibodies in SSc, including their seroclinical associations in a narrative literature review.

show abstract

“…Since the band intensity of IP radiographs was quantified, semiquantitative data portrayal (e.g., scatterplot) with appropriate statistics would also have been helpful. Surprisingly, no association between lung disease and anti‐RPP25 was observed, which might be attributable to the use of forced vital capacity as a “surrogate for interstitial lung disease,” the characteristics of the assay used, and/or the transient characteristics of anti‐RPP25 antibodies (4).…”

Section: Figurementioning

confidence: 99%

Anti‐Th/To Antibodies: Association With Lung Disease and Potential Protection From Systemic Sclerosis–Related Cancer? Comment on the Article by Mecoli et al

Mähler

Satoh

Fritzler

2021

Arthritis & Rheumatology

Self Cite

View full text Add to dashboard Cite

| 545 outcomes. The "reactive" approach is akin to advising that chest pain should be managed without measuring blood pressure or cholesterol, with only the occurrence of myocardial infarction to guide whether therapy was sufficient. The necessary high-quality data and understanding of the biology of gout exist today. Let's not relegate patients to experience the consequences of poorly managed gout by ignoring these data.

show abstract

Seroconversion from Anti-Th/To to Anticentromere Antibodies in a Patient with Systemic Sclerosis

Cited by 5 publications

References 10 publications

Combinations of scleroderma hallmark autoantibodies associate with distinct clinical phenotypes

Combinations of scleroderma hallmark autoantibodies associate with distinct clinical phenotypes

Anti-U11/U12 Antibodies as a Rare but Important Biomarker in Patients with Systemic Sclerosis: A Narrative Review

Anti‐Th/To Antibodies: Association With Lung Disease and Potential Protection From Systemic Sclerosis–Related Cancer? Comment on the Article by Mecoli et al

Contact Info

Product

Resources

About